Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs BAY-2328065 (Primary) ; BAY-2328065 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Bayer
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.
- 21 Jan 2019 Planned End Date changed from 4 Feb 2019 to 11 Feb 2019.
- 20 Dec 2018 Planned End Date changed from 15 Jan 2019 to 4 Feb 2019.